The GOG study using a monoclonal antibody to VEGF and our trial of a VEGFR tyrosine kinase inhibitor shows the value of targeting angiogenesis in combination with chemotherapy in the management of metastatic or relapsed cervical cancer. Here, VEGFA is linked to cervical carcinoma.